PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD). The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is headquartered in Boston, Massachusetts.
What is the ticker symbol for PepGen Inc.? What does PEPG stand for in stocks?
PEPG is the stock ticker symbol of PepGen Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of PepGen Inc. (PEPG)?
As of Fri Dec 20 2024, market cap of PepGen Inc. is 118.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of PEPG stock?
You can check PEPG's fair value in chart for subscribers.
Is PepGen Inc. a good stock to buy?
The fair value guage provides a quick view whether PEPG is over valued or under valued. Whether PepGen Inc. is cheap or expensive depends on the assumptions which impact PepGen Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PEPG.
What is 5 year return on PepGen Inc.'s stock?
In the past 10 years, PepGen Inc. has provided -0.149 (multiply by 100 for percentage) rate of return.